Independent, AI-assisted research · Affiliate disclosure
Peptide Front

Free Tool · Tracker

Peptide FDA Status Tracker

Live regulatory status, FTC enforcement, telehealth prescribers, and vendor shutdown alerts for 12 popular peptides. Data verified against FDA Compounding Bulks Lists and direct telehealth site checks. Last updated April 2026.

Tracked
12
FDA-approved
4
Category 1
1
Category 2
4
Vendor shutdowns
3
Category 2 (excluded from compounding)Grey market — no legal compoundingPreclinical only

BPC-157

Also: Body Protection Compound-157 / PL 14736

Placed on FDA's Category 2 list in November 2023 — meaning licensed 503A pharmacies cannot legally compound it for human use. Still sold as a research chemical and prescribed off-label by some telehealth clinics through grey-market channels.

Trial-Backed Evidence

Strong rodent data on tendon and gut healing. Zero FDA-registered human RCTs as of April 2026 (one Phase 1 ulcer trial registered in 2018 was withdrawn). All human use is anecdotal or off-label.

Regulatory Timeline

  1. Sept 2023
    FDA proposes Category 2
    Cited inadequate safety data and immunogenicity concerns.
  2. Nov 2023
    Final rule published
    503A pharmacies prohibited from compounding BPC-157.
  3. Jul 2024
    FDA reaffirms position
    Compounding industry petition for reconsideration denied.
  4. Feb 2026
    Bipartisan reform bill introduced
    H.R. 4321 would create a peptide review pathway distinct from biologics. Status: in committee.

Recent FTC / FDA Enforcement

  • Aug 2024warning letter
    Multiple Instagram sellers
    Joint FDA/FTC sweep targeting unlawful disease-treatment claims for BPC-157.
  • Mar 2025civil penalty
    Peptide Warriors LLC
    $1.2M settlement for marketing BPC-157 as an FDA-approved injury treatment.

Telehealth Prescribers (cash-pay)

ClinicMonthly cashNotes
Limitless Life$165-$210/moSubscription model. Verifies via internal medical director — accepts grey-market sourcing.
BlokesHRT$199/moBundled with TRT consult. As of April 2026 still listing BPC-157.
AgelessRx$245/moRemoved BPC-157 in Jan 2024 after Cat 2 ruling. Not currently offered.

Verified Vendor Status

  • Science.bio
    Shutdown · verified Jan 14, 2026
    Voluntary shutdown. Refunds issued through Mar 2026.
  • Peptide Sciences
    Shutdown · verified Mar 28, 2026
    Closed citing 'regulatory environment'. Outstanding orders refunded.
  • Pure Rawz
    Operating · verified Apr 18, 2026
    COA-backed batches. US-based fulfillment continues.
  • Amino Asylum
    Operating · verified Apr 16, 2026
    Active. Recent third-party COA dated Mar 2026.

Want the full BPC-157 profile?

Dosing, half-life, study summaries, and stack pairings.

Open profile →
Medical & legal disclaimer: This tracker is informational and reflects publicly available data as of April 2026. It is not legal advice or medical advice. Peptides marketed as research chemicals are not FDA-approved for human use. Consult a licensed clinician and verify current regulatory status before any decision.

Last updated: April 2026.

Related Reading

BPC-157 Legal Status (2026)
What Category 2 actually means for buyers and prescribers.
Compounded Tirzepatide After the Shortage
What changed when FDA declared the shortage resolved.
How to Vet a Research Peptide Vendor
COA standards, sterility testing, and red flags after the 2026 shutdowns.

Get FDA + vendor alerts first

We send a one-email summary the day a peptide changes category, a vendor shuts down, or a major FTC action lands.